EBS Stock Rises on $54M US Smallpox Drug Contract

Key Contract Details

Emergent BioSolutions Inc. (NYSE:EBS) shares increased 4.5% in after-hours trading after the company announced a new $54 million contract. The agreement is with the U.S. Administration for Strategic Preparedness and Response for the delivery of CNJ-016 to support national smallpox preparedness.

Broader Contract Landscape

This contract is an option exercise from an existing 10-year agreement for Vaccinia Immune Globulin Intravenous, a treatment for smallpox vaccination complications. Additionally, Emergent secured $6.6 million in new orders for its ACAM2000 smallpox vaccine from an international government partner, reinforcing that nation's biodefense strategy.

Impact on Market Position

These government contracts strengthen investor confidence and highlight Emergent's critical role in global public health security. The deals follow recent multi-year agreements with the Government of Canada valued up to $140 million CAD, further solidifying the company's revenue stream from government partners.

Summary

The series of successful government agreements strengthens Emergent's financial outlook and its market position as a key supplier of medical countermeasures. Continued focus on biodefense contracts remains a critical factor for the company's performance.

FAQ

Q: What was the main contract announced?
A: A $54 million contract with the U.S. government for CNJ-016, a treatment for smallpox vaccination complications.

Q: How did Emergent BioSolutions' stock react to the news?
A: Its stock, traded under the ticker EBS, rose 4.5% in after-hours trading.

Source: Investing.com